Page 219 - BUAP - Facultad de Medicina - Epigenética en las patologías

tone deacetylase activity and modulates chromatin-mediated neuroplastic-
ity. Neuropharmacology. 2013 Jan; 64: 81-96.
5 Holliday R. Epigenetics: a historical overview. Epigenetics. 2006 Apr-Jun; 1
(2): 76-80.
6 Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J
Neuropathol Exp Neurol. 2013 Feb; 72 (2): 78-90.
7 Koeppen AH. Friedreich’s ataxia: pathology, pathogenesis, and molecular
genetics. J Neurol Sci. 2011 Apr 15; 303 (1-2): 1-12.
8 Kubota T, Miyake K, Hariya N, Mochizuki K. Understanding the epigenetics
of neurodevelopmental disorders and DOHaD. J Dev Orig Health Dis. 2015
Apr; 6 (2): 96-104.
9 Lan J, Hua S, He X, Zhang Y. DNA methyltransferases and methyl-binding
proteins of mammals. Acta Biochim Biophys Sin (Shanghai). 2010 Apr; 42
(4): 243-52.
10 Landgrave-Gómez J, Mercado-Gómez O, Guevara-Guzmán R. Epigenetic
mechanisms in neurological and neurodegenerative diseases. Front Cell
Neurosci. 2015 Feb 27; 9: 58.
11 Li M, Fang Y. Histone variants: the artists of eukaryotic chromatin. Sci China
Life Sci. 2015 Mar; 58 (3): 232-9.
12 Libri V, Yandim C, Athanasopoulos S, Loyse N, Natisvili T, Law PP, Chan PK,
Mohammad T, Mauri M, Tam KT, Leiper J, Piper S, Ramesh A, Parkinson
MH, Huson L, Giunti P, Festenstein R. Epigenetic and neurological effects
and safety of high-dose nicotinamide in patients with Friedreich’s ataxia:
an exploratory, open-label, dose-escalation study. Lancet. 2014 Aug 9; 384
(9942): 504-13.
13 Lynch DR, Fischbeck KH. Nicotinamide in Friedreich’s ataxia: useful or not?
Lancet. 2014 Aug 9; 384 (9942): 474-5.
14 Millan MJ. An epigenetic framework for neurodevelopmental disorders:
from pathogenesis to potential therapy. Neuropharmacology. 2013 May; 68:
2-82.
15 Moore LD, Le T, Fan G. DNA methylation and its basic function.
Neuropsychopharmacology. 2013 Jan; 38 (1): 23-38.

218